Leukemia: Difference between revisions
From IDWiki
(restructured) |
(→) |
||
Line 1: | Line 1: | ||
== |
==Clinical Manifestations== |
||
*Often cytopenia-related symptoms |
*Often cytopenia-related symptoms, including [[anemia]], [[leukopenia]], and [[thrombocytopenia]] |
||
*May also present with [[DIC]], [[tumour lysis syndrome]], or [[leukostasis]] |
|||
==Differential Diagnosis== |
==Differential Diagnosis== |
||
Line 24: | Line 25: | ||
*Rule out [[DIC]] (especially seen in [[APL]]) |
*Rule out [[DIC]] (especially seen in [[APL]]) |
||
==== |
====[[Tumour lysis syndrome]]==== |
||
*2 or more: [[hyperkalemia]], [[hyperphosphatemia]], [[hypocalcemia]], [[hyperuricemia]] |
*2 or more: [[hyperkalemia]], [[hyperphosphatemia]], [[hypocalcemia]], [[hyperuricemia]] |
||
Line 33: | Line 34: | ||
*Do NOT treat [[hypocalcemia]] |
*Do NOT treat [[hypocalcemia]] |
||
==== |
====[[Leukostasis]]==== |
||
*More common in [[AML]] than any other |
*More common in [[AML]] than any other |
||
Line 43: | Line 44: | ||
**No evidence for [[leukopheresis]] |
**No evidence for [[leukopheresis]] |
||
==== |
====Suspected [[APL]]==== |
||
*Consult Hematology overnight |
*Consult Hematology overnight |
||
Line 57: | Line 58: | ||
===Chronic=== |
===Chronic=== |
||
==== |
====AML==== |
||
*Induction with 3+7: 3 days of daunorubicin and 7 days of cytarabine, includes about a month as inpatient |
*Induction with 3+7: 3 days of daunorubicin and 7 days of cytarabine, includes about a month as inpatient |
||
Line 64: | Line 65: | ||
**High/poor risk: 1-2 more cycles, then alloSCT |
**High/poor risk: 1-2 more cycles, then alloSCT |
||
==== |
====APL==== |
||
*ATRA + arsenic trioxide |
*ATRA + arsenic trioxide |
||
==== |
====ALL==== |
||
*Dana-Farber protocol |
*Dana-Farber protocol |
Latest revision as of 15:47, 30 July 2020
Clinical Manifestations
- Often cytopenia-related symptoms, including anemia, leukopenia, and thrombocytopenia
- May also present with DIC, tumour lysis syndrome, or leukostasis
Differential Diagnosis
- Primary: suspect when multiple lineages affected, significant leukocytosis, lymphadenopathy, splenomegaly
- Secondary
- Acute infection (30-50%)
- Chronic inflammation
- Stress (MI, surgery, burn) (30-50%)
- Steroids
- Pregnancy
- Cigarette smoking
Investigations
- Urgent blood film review to r/o APL
Management
Acute
Tumour lysis syndrome
- 2 or more: hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia
- Causes acute kidney injury, seizures, arrhythmias
- Hydration with normal saline (don't supplement electrolytes), target urine output of 80-100 mL/m2/h
- Rasburicase to get rid of uric acid (may need to call Nephrology)
- Treat hyperkalemia
- Do NOT treat hypocalcemia
Leukostasis
- More common in AML than any other
- Lungs and brain most commonly affected
- Cytoreduction
- Induction chemotherapy as soon as possilble
- Overnight, give hydroxyurea 2g q6h
- Can develop tumour lysis syndrome
- No evidence for leukopheresis
Suspected APL
- Consult Hematology overnight
- Start ATRA 45mg/m2 divided BID
- Beware differentiation syndrome, with fever, effusion, dyspnea, hypotension; treated with steroids
- Beware DIC
- Follow q6h bloodwork
- Transfuse platelets ≥ 30
- Cryoprecipitate to keep fibrinogen ≥ 1.5 (regardless of bleeding)
- Plasma to keep INR < 1.5
- AVOID tranexamic acid
Chronic
AML
- Induction with 3+7: 3 days of daunorubicin and 7 days of cytarabine, includes about a month as inpatient
- BM to confirm induction, then consolidation
- Low risk: 2-3 more cycles of same
- High/poor risk: 1-2 more cycles, then alloSCT
APL
- ATRA + arsenic trioxide
ALL
- Dana-Farber protocol
- 2+ years of chemo + steroids
- For Philadelphia positive disease, add imatinib